{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:48Z","timestamp":1758935028472},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"S3","license":[{"start":{"date-parts":[[2005,10,1]],"date-time":"2005-10-01T00:00:00Z","timestamp":1128124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ZS Kardiologie"],"published-print":{"date-parts":[[2005,10]]},"DOI":"10.1007\/s00392-005-1307-x","type":"journal-article","created":{"date-parts":[[2005,10,28]],"date-time":"2005-10-28T19:30:33Z","timestamp":1130527833000},"page":"iii43-iii55","source":"Crossref","is-referenced-by-count":3,"title":["Die Rolle des Lipidstoffwechsels in der Pr\u00e4vention der koronaren Herzerkrankung","The role of lipid metabolism in the prevention of coronary heart disease"],"prefix":"10.1007","volume":"94","author":[{"given":"P.","family":"Mathes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Thiery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"1307_CR1","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1016\/j.ahj.2004.04.027","volume":"148","author":"Brewer","year":"2004","unstructured":"Brewer HB (2004) Focus on highdensity lipoproteins in reducing cardiovascular risk. Am Heart J 148 [Suppl 1]:S14\u2013S18","journal-title":"Am Heart J"},{"key":"1307_CR2","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1185\/030079904125004402","volume":"20","author":"Chapman","year":"2004","unstructured":"Chapman MJ, Assmann G, Fruchart JC, Shepherd J, Sirtori C, European Consensus Panel on HDL-C (2004) Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid\u2014a position paper developed by the European consensus panel on HDL-C. Curr Med Res Opin 20:1253\u20131268","journal-title":"Curr Med Res Opin"},{"key":"1307_CR3","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJMe048326","volume":"352","author":"Ehrenstein","year":"2005","unstructured":"Ehrenstein MR, Jury EC, Mauri C (2005) Statins for atherosclerosis\u2014as good as it gets? N Engl J Med 352:73\u201375","journal-title":"N Engl J Med"},{"key":"1307_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1194\/jlr.R400013-JLR200","volume":"46","author":"Getz","year":"2005","unstructured":"Getz GS (2005) Immune function in atherogenesis. J Lipid Res 46:1\u201310","journal-title":"J Lipid Res"},{"key":"1307_CR5","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/S0092-8674(01)00238-0","volume":"104","author":"Glass","year":"2001","unstructured":"Glass CK, Witztum JL (2001) Atherosclerosis: the road ahead. Cell 104:503\u2013516","journal-title":"Cell"},{"key":"1307_CR6","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1161\/01.CIR.0000133317.49796.0E","volume":"110","author":"Grundy","year":"2004","unstructured":"Grundy SM, Cleeman JI, Merz CNB et al (2004) Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110:227\u2013239","journal-title":"Circulation"},{"key":"1307_CR7","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0195-668X(03)00081-2","volume":"24","author":"Hense","year":"2003","unstructured":"Hense HW, Schulte H, Lowel H, Assmann G, Keil U (2003) Framingham risk function overestimates risk of coronary heart disease in men and women from Germany\u2014results from the MONICA Augsburg and the PROCAM cohorts. Eur Heart J 24:937\u2013945","journal-title":"Eur Heart J"},{"key":"1307_CR8","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/bmj.308.6925.367","volume":"208","author":"Law","year":"1994","unstructured":"Law MR, Wald NJ, Thompson SG (1994) By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 208:367\u2013372","journal-title":"BMJ"},{"key":"1307_CR9","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","volume":"360","author":"MRC","year":"2002","unstructured":"MRC\/BHF (2002) Heart protection study of cholesterol lowering with simvastatin in 20535 high-risk individuals: a randomised placebo-controlled trial. Lancet 360:7\u201322","journal-title":"Lancet"},{"key":"1307_CR10","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0002-9149(00)00910-3","volume":"86","author":"Pedersen","year":"2000","unstructured":"Pedersen TR, Wilhelmsen L, Faergeman O et al. (2000) Follow-up study (4S) of cholesterol lowering. Am J Cardiol 86:257\u2013262","journal-title":"Am J Cardiol"},{"key":"1307_CR11","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","volume":"111","author":"Rader","year":"2003","unstructured":"Rader DJ, Cohen J, Hobbs HH (2003) Monogenic hypercholesterolemia: new insights in pathogenesis and treatment. J Clin Invest 111:1795\u20131803","journal-title":"J Clin Invest"},{"key":"1307_CR12","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","volume":"40","author":"Report","year":"1978","unstructured":"Report from the Committee of Principal Investigators (1978) A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 40:1069\u20131118","journal-title":"Br Heart J"},{"key":"1307_CR13","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1161\/01.CIR.97.15.1446","volume":"97","author":"Sacks","year":"1998","unstructured":"Sacks FM, Moye LA, Davis BR et al. (1998) Relationship between plasma LDL concentration during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial. Circulation 97:1446\u20131452","journal-title":"Circulation"},{"key":"1307_CR14","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0140-6736(03)12858-9","volume":"361","author":"Sever","year":"2003","unstructured":"Sever PS, Daholf B, Poulter NR et al (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentration, in the Anglo-Scandinavian cardiac outcomes trial-lipid lowering arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 361:1140\u20131158","journal-title":"Lancet"},{"key":"1307_CR15","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","volume":"360","author":"Shepherd","year":"2002","unstructured":"Shepherd J, Blauw GJ, Murphy MB et al (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360:1623\u20131630","journal-title":"Lancet"},{"key":"1307_CR16","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1161\/hc1002.105136","volume":"105","author":"Simes","year":"2002","unstructured":"Simes RJ, Marschner IC, Hunt D et al (2002) Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105:1162\u20131169","journal-title":"Circulation"},{"key":"1307_CR17","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1161\/01.CIR.0000133427.35111.67","volume":"109","author":"Smith","year":"2004","unstructured":"Smith SC Jr, Jackson R, Pearson TA et al (2004) Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. Circulation 109:3112\u20133121","journal-title":"Circulation"},{"key":"1307_CR18","first-page":"1383","volume":"344","author":"The","year":"1994","unstructured":"The Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S). Lancet 344:1383\u20131389","journal-title":"Lancet"},{"key":"1307_CR19","doi-asserted-by":"crossref","unstructured":"Thiery J, Teupser D, Fiedler GM (2003) Lipide und St\u00f6rungen des Lipoproteinstoffwechsels In: Renz H (Hrsg) Integrative Klinische Chemie und Laboratoriumsmedizin, 1. Aufl. de Gruyter, Berlin","DOI":"10.1515\/9783110200133.67"},{"key":"1307_CR20","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1161\/01.CIR.97.15.1440","volume":"97","author":"WOSCOPS","year":"1998","unstructured":"WOSCOPS (1998) Influence of pravastatin and plasma lipids on clinical events in the West of Scotland coronary prevention study (WOSCOPS). Circulation 97:1440\u20131445","journal-title":"Circulation"}],"container-title":["Zeitschrift f\u00fcr Kardiologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-005-1307-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00392-005-1307-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00392-005-1307-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T06:56:51Z","timestamp":1683269811000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00392-005-1307-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,10]]},"references-count":20,"journal-issue":{"issue":"S3","published-print":{"date-parts":[[2005,10]]}},"alternative-id":["1307"],"URL":"https:\/\/doi.org\/10.1007\/s00392-005-1307-x","relation":{},"ISSN":["0300-5860","1435-1285"],"issn-type":[{"value":"0300-5860","type":"print"},{"value":"1435-1285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,10]]}}}